Factor V Leiden: The Copenhagen City Heart Study and 2 meta-analyses by Klaus Juul, Anne Tybjærg-Hansen, Rolf Steffensen, Steen Kofoed, Gorm Jensen, and.

Slides:

Advertisements

Similar presentations

Association between beta2-glycoprotein I plasma levels and the risk of myocardial infarction in older men by Bas de Laat, Philip G. de Groot, Ronald H.

Advertisements

Baseline Characteristics of Individuals From the General Population by Quartiles of Triglyceride Levels a Børge G. Nordestgaard, et al. JAMA 2007;298:

Flow Diagram of the Trial Selection Process Jeffrey S. Berger et al, JAMA. 2006;295:

Silent cerebral infarcts occur despite regular blood transfusion therapy after first strokes in children with sickle cell disease by Monica L. Hulbert,

Time from diagnosis to treatment initiation predicts survival in younger, but not older, acute myeloid leukemia patients by Mikkael A. Sekeres, Paul Elson,

Date of download: 7/8/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Reduced-Function CYP2C19 Genotype and Risk of Adverse.

Trends in Hospitalizations and Outcomes for Acute Cardiovascular Disease and Stroke, 1999–2011CLINICAL PERSPECTIVE by Harlan M. Krumholz, Sharon-Lise T.

EBV-positive diffuse large B-cell lymphoma of the elderly by Chi Young Ok, Thomas G. Papathomas, L. Jeffrey Medeiros, and Ken H. Young Blood Volume 122(3):

Generating AML-Specific Peripheral Blood Autologous Cytotoxic T-Lymphocytes (CTLs)‏ by Rohtesh S. Mehta, Xiaohua Chen, Antony Jeyaraj, and Paul Szabolcs.

Discontinuation of medication after nonfatal event: MI

APOC3 LOF heterozygotes have lower IVD and IHD risks due to lower RC

Comparison of Triflusal and Aspirin for Prevention of Vascular Events in Patients After Cerebral Infarction by Jordi Matías-Guiu, José M. Ferro, José Alvarez-Sabín,

Hypocholesterolemia Is Independently Associated with Decreased Survival in Patients with Primary Myelofibrosis: An Analysis of Lipid Profiles in 558 Myeloproliferative.

Association Between Mycoplasma Pneumonia and Increased Risk of Ischemic Stroke by Chia-Hung Chiang, Chin-Chou Huang, Wan-Leong Chan, Yu-Chun Chen, Tzeng-Ji.

by Robert A. Kyle, Morie A. Gertz, Philip R. Greipp, Thomas E

Second Allogeneic Hematopoietic Cell Transplantation in Patients with Hematologic Malignancies for Relapse After First Allografts by Boglarka Gyurkocza,

by Nadine Martel, James Lee, and Philip S. Wells

Combination of 4Ts score and PF4/H-PaGIA for diagnosis and management of heparin-induced thrombocytopenia: prospective cohort study by Lori-Ann Linkins,

Autologous stem cell transplantation followed by a dose-reduced allograft induces high complete remission rate in multiple myeloma by Nicolaus Kröger,

Next-generation leukemia immunotherapy

Predicting recurrence after unprovoked venous thromboembolism: prospective validation of the updated Vienna Prediction Model by Tobias Tritschler, Marie.

A Clinical Evaluation of the International Lymphoma Study Group Classification of Non-Hodgkin's Lymphoma Blood Volume 89(11): June 1, 1997 ©1997.

Bleeding in carriers of hemophilia

How I treat elderly patients with myeloma

Nonmyeloablative conditioning for relapsed follicular lymphoma

Superior Survival after Autologous vs

Symptomatic and Incidental Venous Thromboembolic Disease Are Both Associated With Mortality In Patients With Prostate Cancer by Shruti Chaturvedi, Surbhi.

by Petri Salven, Lasse Teerenhovi, and Heikki Joensuu

Autologous Transplantation Therapy for Chronic Myelogenous Leukemia

Hepatic injury after nonmyeloablative conditioning followed by allogeneic hematopoietic cell transplantation: a study of 193 patients by William J. Hogan,

What is a true ALCL? by Wolfram Klapper Blood Volume 124(9):

by Jayesh Mehta Blood Volume 112(2): July 15, 2008

by Douglas D. Ross, Judith E. Karp, Tar T. Chen, and L. Austin Doyle

Stage C or not stage C…? by Claire Dearden Blood

CXCR4 expression is associated with survival in familial chronic lymphocytic leukemia, but CD38 expression is not by Naoko Ishibe, Maher Albitar, Iman.

Treatment-related risk factors of inhibitor development in previously untreated patients with hemophilia A: the CANAL cohort study by Samantha C. Gouw,

Cytokine-Release Syndrome in Patients With B-Cell Chronic Lymphocytic Leukemia and High Lymphocyte Counts After Treatment With an Anti-CD20 Monoclonal.

P2Y12 blockade versus placebo; risk ratio with 95% CIs for the primary composite end point of cardiovascular death, non-fatal myocardial infarction and.

When Guidelines Cause Hypertension

Flow chart of the study population according to thienopyridines used in the FAST-MI registry in patients with STEMI and NSTEMI. FAST-MI, French Registry.

by Santosh L. Saraf, Xu Zhang, Tamir Kanias, James P. Lash, Robert E

by Fumiko Chino, Arif H. Kamal, Junzo Chino, and Thomas W. LeBlanc

Ofatumumab in combination with ICE or DHAP chemotherapy in relapsed or refractory intermediate grade B-cell lymphoma by Matthew J. Matasar, Myron S. Czuczman,

Predicted number of joint bleeds according to factor activity level and age group for patients with hemophilia A or B based on a regression model. Predicted.

An ACCORD BP sub-analysis HR: 1.06; 95%CI: ; P=0.61

Cumulative survival without events during 1 year of follow-up in patients treated with zofenopril (n=1808), placebo (n=951), lisinopril (n=520) or ramipril.

Associations between atmospheric chemistry transport model pollution concentrations at lags 0, 1 and 2 and myocardial infarction (% change in risk per.

Cumulative survival without events during the first 42 days of treatment with zofenopril (n=1808), placebo (n=951), lisinopril (n=520) or ramipril (n=351)

Figure 2 Kaplan-Meier survival graphs for 10-year risks of overall and post-90-day recurrent ischemic stroke (IS) and death Kaplan-Meier survival graphs.

by H. Ddungu, M. Waiswa, R. Kruisselbrink, P. Kagoma, and M. Crowther

A Single Participant Exposed Twice to an Inflammatory Stimulus

Cumulative incidence of cardiovascular events according to medication group in participants of the 4D study with an LDL-C in its fourth quartile at baseline.

An ACCORD BP sub-analysis HR: 1.06; 95%CI: ; P=0.61

Erratum in Ledru et al. Alteration of tumor necrosis factor–α T-cell homeostasis following potent antiretroviral therapy: contribution to the development.

An example of the predicted risk of final infarct for 2 patients with acute ischemic stroke using 2 neural networks trained, respectively, on patients.

Survival based on V gene mutation status and CD38 expression among B-CLL patients who stratify to the Rai intermediate risk category. Survival based on.

Prasugrel versus clopidogrel; risk ratio with 95% CIs for the primary composite end point of cardiovascular death, non-fatal myocardial infarction and.

Primary hemostasis, coagulation and inflammatory parameters

Rituximab immunotherapy: it’s getting personal

Time-dependent survival estimation in post–polycythemia vera myelofibrosis. Time-dependent survival estimation in post–polycythemia vera myelofibrosis.

Mesenchymal Stem Cell-Derived Vesicles Reverse Hematopoietic Radiation Damage by Sicheng Wen, Laura R Goldberg, Mark S Dooner, John L Reagan, and Peter.

Hepatosplenic T-Cell Lymphoma: Clinicopathological Features and Treatment Outcomes: Report From The North American Peripheral T-Cell Lymphoma Consortium.

A Novel Risk Assessment Model to Predict Venous Thromboembolism (VTE) in Cancer Inpatients: The Canclot Score by Dana E. Angelini, M. Todd Greene, Julie.

Initial treatment of CLL: integrating biology and functional status

A meta-analysis of low-molecular-weight heparin to prevent pregnancy loss in women with inherited thrombophilia by Leslie Skeith, Marc Carrier, Risto Kaaja,

Prevalence of acute myocardial infarction (AMI) or other cardiovascular events (CVEs) according to a) Pneumonia Severity Index (PSI) risk classes and b)

Prasugrel and ticagrelor versus clopidogrel; risk ratio with 95% CIs for the primary composite end point of cardiovascular death, non-fatal myocardial.

Balancing bleeding in brain metastases

Cold agglutinin disease

Proportions of the social isolation—AMI and stroke excess risk mediated by biological, behavioural, socioeconomic and health-related factors. Proportions.

Presentation transcript:

Factor V Leiden: The Copenhagen City Heart Study and 2 meta-analyses by Klaus Juul, Anne Tybjærg-Hansen, Rolf Steffensen, Steen Kofoed, Gorm Jensen, and Børge Grønne Nordestgaard Blood Volume 100(1):3-10 July 1, 2002 ©2002 by American Society of Hematology

Study design. Klaus Juul et al. Blood 2002;100:3-10 ©2002 by American Society of Hematology

Survival functions for FVL carriers (heterozygotes + homozygotes) and noncarriers in The Copenhagen City Heart Study. Klaus Juul et al. Blood 2002;100:3-10 ©2002 by American Society of Hematology

Meta-analyses on myocardial infarction risk in FVL carriers (heterozygotes + homozygotes).Studies are listed according to their weight. Klaus Juul et al. Blood 2002;100:3-10 ©2002 by American Society of Hematology

Meta-analyses on ischemic stroke risk in FVL carriers (heterozygotes + homozygotes).Studies are listed according to their weight. Klaus Juul et al. Blood 2002;100:3-10 ©2002 by American Society of Hematology